Pre Bell: OSI Pharma, Genentech Stumble
444613
Shares of pharmaceutical companies OSI  Pharmaceuticals Inc. OSIP.O and Genentech Inc. DNA.N fell  sharply before the bell on Friday on concerns about the price  and a warning label on a key new drug the two collaborated to  produce.
657640
GlaxoSmithKline may be temporarily down, but it's not out.
372947
Stocks of branded and generic drug makers closed down a bit Tuesday as clinical study results mixed with merger updates. One of the big winners on the day was Nektar Therapeutics, on news that Exubera, the
348531
That would be small consolation to pharma investors.
632359
Shares of Atherogenics Inc. opened down 7.2 percent on the Nasdaq Wednesday following a pre-market report that the drug developer is abandoning further clinical trials of its AGIX-4207 treatment for rheumatoid arthritis.
225228
BOSTON (CBS.MW) - Shares of Genentech were halted on Monday as the company announced that its oncology drug Avastin had been shown to extend the lives of some patients stricken with advanced colorectal cancer.
380448
Biotech company OSI Pharmaceuticals Inc. and biotech giant Genentech Inc. reported Friday that the Food and Drug Administration approved their Tarceva cancer treatment for patients with advanced non-small-cell
438480
Credit Suisse First Boston said that an announcement from Onyx Pharmaceuticals (nasdaq: ONXX - news - people ) is &quot;good news&quot; for Genentech (nyse: DNA - news - people ) and its Avastin treatment.
421575
Genentech and OSI Pharmaceuticals won federal approval yesterday to sell Tarceva, a pill to treat lung cancer. The approval by the Food and Drug Administration came well before the agency&#39;s
628857
Biotechnology company Genentech Inc  said on Monday its fourth-quarter profit rose 6.4 percent, but sales of its blockbuster cancer drug and others fell short of investor expectations, sending the company's shares lower.
140996
A day late and possibly several millions of dollars short. That's the scenario facing one drug manufacturer unless it can get a helping hand from Congress.
643643
Drug-maker posts tepid results as it bides time before new products hit the market.
152243
Shares in BiogenIdec (BIIB:Nasdaq - news - research) and Elan (ELN:NYSE - news - research)rose early Monday after the companies released what they described as &quot;compelling&quot; phase III test results for their multiple sclerosis drug Antegren.
680034
An executive of the company that makes the diabetes drug Avandia said a researcher who was among the first to link it to heart problems would be held liable for the $4 billion GlaxoSmithKline PLC lost in stock value as a result of his findings, Dr. John B. Buse testified before congressional investigators yesterday.
268759
The larger pharmaceutical drops out of daclizumab development.
190038
Shares of Axonyx Inc.  plunged 62 percent before the bell on Monday after the drug developer said its experimental Alzheimer's treatment failed to achieve statistical significance in a clinical trial.
249246
Genentech and Biogen Idec's drug shows positive results against multiple sclerosis.